Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Amplified”

72 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 72 results

Testing effectiveness (Phase 2)Looking for participantsNCT07220135
What this trial is testing

Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer

Who this might be right for
Breast Cancer
University of Kansas Medical Center 100
Large-scale testing (Phase 3)Study completedNCT00486954
What this trial is testing

Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer

Who this might be right for
Neoplasms, Gastrointestinal Tract
GlaxoSmithKline 273
Testing effectiveness (Phase 2)Study completedNCT00356811
What this trial is testing

Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 57
Testing effectiveness (Phase 2)Study completedNCT01050322
What this trial is testing

Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment.

Who this might be right for
BRMS1Performance Status Zero to Two for Beginning the StudyPatient With a Maximum of One Chemotherapy+1 more
Latin American Cooperative Oncology Group 142
Large-scale testing (Phase 3)Study completedNCT00005970
What this trial is testing

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

Who this might be right for
Breast AdenocarcinomaHER2 Positive Breast CarcinomaStage IA Breast Cancer AJCC v7+4 more
National Cancer Institute (NCI) 3,436
Testing effectiveness (Phase 2)Looking for participantsNCT06581432
What this trial is testing

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

Who this might be right for
Solid Tumours
Boehringer Ingelheim 430
Testing effectiveness (Phase 2)Active Not RecruitingNCT06840483
What this trial is testing

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

Who this might be right for
Breast Cancer
BicycleTx Limited 66
Large-scale testing (Phase 3)Study completedNCT00490139
What this trial is testing

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 8,381
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07570966
What this trial is testing

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 217
Post-approval studies (Phase 4)Looking for participantsNCT07195344
What this trial is testing

Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.

Who this might be right for
Locally Advanced or Metastatic Breast Cancers
Institut Claudius Regaud 210
Testing effectiveness (Phase 2)Study completedNCT00958971
What this trial is testing

Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 43
Testing effectiveness (Phase 2)Looking for participantsNCT05672524
What this trial is testing

Tucatinib and Trastuzumab in People With Rectal Cancer

Who this might be right for
Adenocarcinoma of the RectumLocally Advanced Rectal AdenocarcinomaRectal Adenocarcinoma+2 more
Memorial Sloan Kettering Cancer Center 37
Testing effectiveness (Phase 2)Study completedNCT00258349
What this trial is testing

Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer

Who this might be right for
Breast CancerMale Breast CancerRecurrent Breast Cancer+3 more
National Cancer Institute (NCI) 16
Testing effectiveness (Phase 2)Study completedNCT01111825
What this trial is testing

Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

Who this might be right for
Breast Cancer
Puma Biotechnology, Inc. 99
Testing effectiveness (Phase 2)Study completedNCT00591851
What this trial is testing

Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 70
Testing effectiveness (Phase 2)Study completedNCT01614522
What this trial is testing

A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2

Who this might be right for
Stomach NeoplasmsCancer of StomachCancer of the Stomach+2 more
ASLAN Pharmaceuticals 24
Testing effectiveness (Phase 2)Study completedNCT01670877
What this trial is testing

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Who this might be right for
Breast Neoplasms
Washington University School of Medicine 56
Testing effectiveness (Phase 2)Study completedNCT00721630
What this trial is testing

Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 24
Not applicableStudy completedNCT00535509
What this trial is testing

Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer

Who this might be right for
Breast Cancer
King Faisal Specialist Hospital & Research Center 285
Testing effectiveness (Phase 2)Ended earlyNCT00820924
What this trial is testing

Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 23
Load More Results